Celon Pharma SA Asset Resilience Ratio
Celon Pharma SA asset resilience ratio. Celon Pharma SA (CLN) has an Asset Resilience Ratio of 0.11% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Celon Pharma SA balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Celon Pharma SA (2012–2025)
Asset resilience ratio of Celon Pharma SA from 2012 to 2025. This chart shows how Celon Pharma SA's Asset Resilience Ratio has changed over time. See Celon Pharma SA (CLN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Celon Pharma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Celon Pharma SA's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł747.00K | 0.11% |
| Total Liquid Assets | zł747.00K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Celon Pharma SA maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Celon Pharma SA Industry Peers by Asset Resilience Ratio
Compare Celon Pharma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Celon Pharma SA Asset Resilience Ratio by Year (2012–2025)
Celon Pharma SA asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Celon Pharma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.13% | zł599.00K ≈ $164.85K |
zł457.46 Million ≈ $125.90 Million |
-8.74pp |
| 2024-12-31 | 8.87% | zł48.24 Million ≈ $13.28 Million |
zł543.79 Million ≈ $149.66 Million |
-5.56pp |
| 2023-12-31 | 14.44% | zł82.18 Million ≈ $22.62 Million |
zł569.31 Million ≈ $156.68 Million |
+1.02pp |
| 2022-12-31 | 13.42% | zł81.72 Million ≈ $22.49 Million |
zł608.93 Million ≈ $167.59 Million |
+2.14pp |
| 2021-12-31 | 11.28% | zł79.75 Million ≈ $21.95 Million |
zł707.14 Million ≈ $194.61 Million |
+11.28pp |
| 2020-12-31 | 0.00% | zł13.00K ≈ $3.58K |
zł703.64 Million ≈ $193.65 Million |
+0.00pp |
| 2019-12-31 | 0.00% | zł318.00 ≈ $87.52 |
zł591.35 Million ≈ $162.75 Million |
-9.66pp |
| 2018-12-31 | 9.66% | zł54.48 Million ≈ $14.99 Million |
zł563.67 Million ≈ $155.13 Million |
+9.68pp |
| 2017-12-31 | -0.02% | zł-90.59K ≈ $-24.93K |
zł525.05 Million ≈ $144.50 Million |
-0.33pp |
| 2016-12-31 | 0.31% | zł1.44 Million ≈ $395.83K |
zł464.32 Million ≈ $127.79 Million |
-0.07pp |
| 2015-12-31 | 0.38% | zł632.65K ≈ $174.12K |
zł168.29 Million ≈ $46.32 Million |
-0.18pp |
| 2014-12-31 | 0.56% | zł590.14K ≈ $162.42K |
zł105.44 Million ≈ $29.02 Million |
+0.35pp |
| 2013-12-31 | 0.21% | zł175.65K ≈ $48.34K |
zł82.59 Million ≈ $22.73 Million |
0.00pp |
| 2012-12-31 | 0.22% | zł150.13K ≈ $41.32K |
zł69.80 Million ≈ $19.21 Million |
-- |
About Celon Pharma SA
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.